PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany. jonathan.rilinger@uniklinik-freiburg.de.\', \'Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany. jonathan.rilinger@uniklinik-freiburg.de.\', \'Division of Infectious Diseases, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.\', \'Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.\', \'Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s13063-020-04447-3
?:doi
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 32493514
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all